Fusions involving the NRG1 gene are rare in solid tumors, with an overall prevalence of less than 1% across various tumor types.2 However, they are notably enriched in specific malignancies, such as invasive mucinous adenocarcinomas (IMA), a subtype of non-small cell lung cancer (NSCLC), and in KRAS wild-type pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene KRAS and non-small cell lung carcinoma.